Literature DB >> 21416235

Ningdong granule: a complementary and alternative therapy in the treatment of attention deficit/hyperactivity disorder.

Ji-Jun Li1, Zai-Wang Li, Shu-Zhen Wang, Fang-Hua Qi, Lin Zhao, Hong Lv, An-Yuan Li.   

Abstract

BACKGROUND: Attention deficit/hyperactivity disorder (ADHD) is a common neurobehavioral and neuropsychiatric disorder in school-age children, and recent studies provide evidence implicating the metabolic abnormalities of dopamine (DA) for its pathophysiology. Methylphenidate, a kind of psychostimulant, is widely used in the treatment of ADHD, but some patients do not respond to it or cannot bear its side effects. As a traditional Chinese medicine preparation, Ningdong granule (NDG) has been used in the treatment of ADHD for several years in China. However, a systematical pharmacological study on its safety and mechanism still remains obscure.
OBJECTIVE: This paper aims to evaluate the efficiency, safety, and possible mechanism of NDG on ADHD children compared to methylphenidate.
METHODS: Seventy-two ADHD children were recruited to perform an 8-week, randomized, methylphenidate-controlled, doubled-blinded trial. The subjects were equally assigned to two groups receiving either NDG 5 mg/kg/day or methylphenidate 1 mg/kg/day for 8 weeks. The efficiency was assessed by the Teacher and Parent ADHD Rating Scales every 2 weeks for a total of 8 weeks. The side effects were recorded during the study. Blood, urine, and stool routine samples, liver and renal function test, and DA and homovanillic acid (HVA) concentration in sera were tested at the beginning and end of the trial.
RESULTS: NDG ameliorated ADHD symptoms after an 8-week medication with fewer side effects compared to methylphenidate (P < 0.05). The result also showed NDG to be safe and tolerable for ADHD children as monitored by the blood, urine, and stool analysis and liver and renal function for 8 weeks (P < 0.05). Moreover, the level of HVA in sera increased in NDG-treated group (P < 0.05), while the content of DA had no significant change during the study. An analysis of Pearson correlation coefficients also showed that the increased content of HVA in sera was associated with the improved scores of Teacher and Parent ADHD Rating Scales.
CONCLUSIONS: Compared to methylphenidate, NDG is effective and safe for ADHD children in the short term, increases the HVA concentration in sera to regulate DA metabolism, and promises to be an alternative medication, safely and effectively.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21416235     DOI: 10.1007/s00213-011-2238-z

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  58 in total

Review 1.  Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: results from imaging studies.

Authors:  Nora D Volkow; Joanna S Fowler; Gene Jack Wang; Yu Shin Ding; Samuel J Gatley
Journal:  Eur Neuropsychopharmacol       Date:  2002-12       Impact factor: 4.600

Review 2.  The mechanism of action of drugs used to treat attention-deficit hyperactivity disorder: focus on catecholamine receptor pharmacology.

Authors:  A Shenker
Journal:  Adv Pediatr       Date:  1992

3.  Plasma homovanillic acid correlates inversely with history of learning problems in healthy volunteer and personality disordered subjects.

Authors:  Emil F Coccaro; Sharon L Hirsch; Mark A Stein
Journal:  Psychiatry Res       Date:  2006-11-16       Impact factor: 3.222

Review 4.  The other face of depression, reduced positive affect: the role of catecholamines in causation and cure.

Authors:  David Nutt; Koen Demyttenaere; Zoltan Janka; Trond Aarre; Michel Bourin; Pier Luigi Canonico; Jose Luis Carrasco; Steven Stahl
Journal:  J Psychopharmacol       Date:  2006-10-18       Impact factor: 4.153

Review 5.  Review of pharmacotherapy options for the treatment of attention-deficit/hyperactivity disorder (ADHD) and ADHD-like symptoms in children and adolescents with developmental disorders.

Authors:  Brieana M Rowles; Robert L Findling
Journal:  Dev Disabil Res Rev       Date:  2010

Review 6.  Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association.

Authors:  L S Goldman; M Genel; R J Bezman; P J Slanetz
Journal:  JAMA       Date:  1998-04-08       Impact factor: 56.272

7.  Dopaminergic dysfunction in attention deficit hyperactivity disorder (ADHD), differences between pharmacologically treated and never treated young adults: a 3,4-dihdroxy-6-[18F]fluorophenyl-l-alanine PET study.

Authors:  Andrea G Ludolph; Jan Kassubek; Klaus Schmeck; Cornelia Glaser; Arthur Wunderlich; Andreas K Buck; Sven N Reske; Joerg M Fegert; Felix M Mottaghy
Journal:  Neuroimage       Date:  2008-02-29       Impact factor: 6.556

8.  Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial.

Authors:  Bahman Salehi; Reza Imani; Mohammad Reza Mohammadi; Jalil Fallah; Mohammad Mohammadi; Ahmad Ghanizadeh; Ali Akbar Tasviechi; Ardalan Vossoughi; Shams-Ali Rezazadeh; Shahin Akhondzadeh
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2009-10-05       Impact factor: 5.067

9.  A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder.

Authors:  Manijeh Kahbazi; Aboulfazl Ghoreishi; Fatemeh Rahiminejad; Mohammad-Reza Mohammadi; Abbas Kamalipour; Shahin Akhondzadeh
Journal:  Psychiatry Res       Date:  2009-05-12       Impact factor: 3.222

10.  Involvement of dopamine (DA)/serotonin (5-HT)/sigma (sigma) receptor modulation in mediating the antidepressant action of ropinirole hydrochloride, a D2/D3 dopamine receptor agonist.

Authors:  Ashish Dhir; S K Kulkarni
Journal:  Brain Res Bull       Date:  2007-05-30       Impact factor: 4.077

View more
  6 in total

Review 1.  Use of Non-Pharmacological Supplementations in Children and Adolescents with Attention Deficit/Hyperactivity Disorder: A Critical Review.

Authors:  Eleonora Rosi; Silvia Grazioli; Filippo Maria Villa; Maddalena Mauri; Erica Gazzola; Marco Pozzi; Massimo Molteni; Maria Nobile
Journal:  Nutrients       Date:  2020-05-28       Impact factor: 5.717

Review 2.  Psychiatric Disorders and Polyphenols: Can They Be Helpful in Therapy?

Authors:  Jana Trebatická; Zdeňka Ďuračková
Journal:  Oxid Med Cell Longev       Date:  2015-06-09       Impact factor: 6.543

3.  Herbal medicines for treating tic disorders: a systematic review of randomised controlled trials.

Authors:  Yun Hee Kim; Chang-Gue Son; Bon-Cho Ku; Hye Won Lee; Hyun Sook Lim; Myeong Soo Lee
Journal:  Chin Med       Date:  2014-02-07       Impact factor: 5.455

Review 4.  Natural Product-Derived Treatments for Attention-Deficit/Hyperactivity Disorder: Safety, Efficacy, and Therapeutic Potential of Combination Therapy.

Authors:  James Ahn; Hyung Seok Ahn; Jae Hoon Cheong; Ike Dela Peña
Journal:  Neural Plast       Date:  2016-02-04       Impact factor: 3.599

Review 5.  Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.

Authors:  Ole Jakob Storebø; Nadia Pedersen; Erica Ramstad; Maja Lærke Kielsholm; Signe Sofie Nielsen; Helle B Krogh; Carlos R Moreira-Maia; Frederik L Magnusson; Mathilde Holmskov; Trine Gerner; Maria Skoog; Susanne Rosendal; Camilla Groth; Donna Gillies; Kirsten Buch Rasmussen; Dorothy Gauci; Morris Zwi; Richard Kirubakaran; Sasja J Håkonsen; Lise Aagaard; Erik Simonsen; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2018-05-09

Review 6.  Tourette's disorder in children and adolescents.

Authors:  Donald E Greydanus; Julia Tullio
Journal:  Transl Pediatr       Date:  2020-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.